{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:28:31Z","timestamp":1791037711636,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4482,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.exphem.2009.12.007","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T04:16:40Z","timestamp":1262837800000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression"],"prefix":"10.1016","volume":"38","author":[{"given":"Andrea","family":"Borgerding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Engelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wienands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2009.12.007_bib1","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib2","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2009.12.007_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib6","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2009.12.007_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond","author":"Bello","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2009.12.007_bib8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2009.12.007_bib9","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","article-title":"Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response","volume":"10","author":"Gluck","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2009.12.007_bib11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib12","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2009.12.007_bib13","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.12.007_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1693","article-title":"Mechanism of cytotoxicity induced by\u00a0chimeric mouse human monoclonal antibody IDEC-C2B8 in\u00a0CD20-expressing lymphoma cell lines","volume":"204","author":"Flieger","year":"2000","journal-title":"Cell Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.exphem.2009.12.007_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/j.exphem.2009.12.007_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1385\/IR:30:1:029","article-title":"The role of CD94\/NKG2 in innate and adaptive immunity","volume":"30","author":"Gunturi","year":"2004","journal-title":"Immunol Res"},{"key":"10.1016\/j.exphem.2009.12.007_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.20.092501.134942","article-title":"diverse, rapidly evolving receptors of innate and adaptive immunity","volume":"20","author":"Vilches","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2009.12.007_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00651.x","article-title":"Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias","volume":"224","author":"Moretta","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2009.12.007_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.180.2.687","article-title":"A natural killer cell receptor specific for a major histocompatibility complex class I molecule","volume":"180","author":"Daniels","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2009.12.007_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-065X.1997.tb00947.x","article-title":"Arousal and inhibition of human NK cells","volume":"155","author":"Lanier","year":"1997","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2009.12.007_bib24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.7863326","article-title":"Peptide specificity in the recognition of MHC class I by natural killer cell clones","volume":"267","author":"Malnati","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.exphem.2009.12.007_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-3083.2007.02058.x","article-title":"Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors","volume":"67","author":"Hasenkamp","year":"2008","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-3083.2006.01803.x","article-title":"Resistance against natural killer cell cytotoxicity: analysis of mechanisms","volume":"64","author":"Hasenkamp","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1479-5876-2-31","article-title":"Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay","volume":"2","author":"Shafer-Weaver","year":"2004","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.exphem.2009.12.007_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2249.2004.02569.x","article-title":"Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system","volume":"137","author":"Tejde","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002620050567","article-title":"Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity","volume":"48","author":"Lehmann","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2009.12.007_bib30","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.4049\/jimmunol.180.9.6392","article-title":"Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy","volume":"180","author":"Binyamin","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/intimm\/13.8.1043","article-title":"Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors","volume":"13","author":"Warren","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.4049\/jimmunol.179.2.854","article-title":"KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro","volume":"179","author":"Chewning","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib33","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.4049\/jimmunol.177.10.6904","article-title":"Segregation of HLA-C from ICAM-1 at NK cell immune synapses is controlled by its cell surface density","volume":"177","author":"Almeida","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2007.06631.x","article-title":"Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia","volume":"138","author":"Pfeiffer","year":"2007","journal-title":"Br\u00a0J Haematol"},{"key":"10.1016\/j.exphem.2009.12.007_bib35","first-page":"1759","article-title":"Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling","volume":"26","author":"Stein","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.exphem.2009.12.007_bib36","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/immu.200390014","article-title":"Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer","volume":"33","author":"Bauernhofer","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.exphem.2009.12.007_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2009.12.007_bib39","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.12.007_bib40","first-page":"10","article-title":"In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth","volume":"9","author":"Riond","year":"2009","journal-title":"Cancer Immun"},{"key":"10.1016\/j.exphem.2009.12.007_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/030097401316909530","article-title":"Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis","volume":"30","author":"Sigidin","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.exphem.2009.12.007_bib42","first-page":"277","article-title":"Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis","volume":"7","author":"Skurkovich","year":"2001","journal-title":"Mult Scler"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09004883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09004883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:28:08Z","timestamp":1759566488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X09004883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0301472X09004883"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2009.12.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2009.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}